• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Marpai Inc.

    5/29/24 11:54:48 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MRAI alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001841573
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Marpai, Inc.
    SEC File Number
    001-40904
    Address of Issuer
    615 Channelside Dr #207
    Tampa
    FLORIDA
    33602
    Phone
    855-389-7330
    Name of Person for Whose Account the Securities are To Be Sold
    Mohsen Moazami
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Shares Class A
    APEX CLEARING
    350 N ST. PAUL ST
    SUITE 300
    DALLAS � TX � 75201
    1500013500.001031000005/28/2024
    OTCQX


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Shares Class A05/23/2024Stock Grant VestingMarpai incCheckbox not checked1500005/23/2024N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/28/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Mohsen Moazami

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MRAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MRAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI ANNOUNCES 2026 MOMENTUM AND KEY PARTNERSHIP EXPANSION

    Renews Aetna Signature Administrator Network Agreement and Enhances Cost Containment with Faircost Optimizer TAMPA, Fla., Dec. 1, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced significant positive momentum heading into the new year, highlighted by a better-than-expected sales cycle for 2026 and the renewal of its critical network access agreement with Aetna. The Company reports a robust sales cycle, securing a volume of new clients for January 1, 2026, that surpasses internal expectations, reinforcing its path to scalable growt

    12/1/25 4:04:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    Continued Turnaround Driven by Cost Discipline and Operational Efficiency; Positioned for Strong 2026 Growth TAMPA, Fla., Nov. 12, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced third quarter 2025 results that mark another quarter of significant operational and financial improvement, underscoring the success of its transformation strategy and the Company's emergence as a disciplined, scalable growth platform heading into 2026. For the third quarter ended September 30, 2025, Marpai continued its turnaround trajectory, achieving meaningful advances in cost control,

    11/12/25 5:39:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Chief Operating Officer Scrip Dallas was granted 100,000 shares (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:48:30 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MRAI
    SEC Filings

    View All

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Shiv Sagiv bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 23% to 272,000 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:49:18 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Director Pons Robert M bought $50,000 worth of shares (50,000 units at $1.00), increasing direct ownership by 16% to 359,200 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:47:30 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Marpai Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement

    8-K - Marpai, Inc. (0001844392) (Filer)

    1/23/26 4:02:33 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Marpai Inc.

    SCHEDULE 13G/A - Marpai, Inc. (0001844392) (Subject)

    1/9/26 2:43:57 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Marpai, Inc. (0001844392) (Filer)

    12/22/25 7:14:49 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Leadership Updates

    Live Leadership Updates

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

    Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

    5/13/25 9:01:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions

    STUART, Fla., Jan. 22, 2025 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a  competitively priced self-funded health plan to the market. By utilizing the strength of Vitable's Direct Primary Care (DPC), a health plan, and stop-loss coverage, Health In Tech seeks to offer low quotes on their eDIYBS platform, and to set an ambitious standard in affordability and efficiency. Vitable's enhanced primary care plan co

    1/22/25 5:00:00 PM ET
    $HIT
    $MRAI
    Specialty Insurers
    Finance
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Financials

    Live finance-specific insights

    View All

    MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    Continued Turnaround Driven by Cost Discipline and Operational Efficiency; Positioned for Strong 2026 Growth TAMPA, Fla., Nov. 12, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced third quarter 2025 results that mark another quarter of significant operational and financial improvement, underscoring the success of its transformation strategy and the Company's emergence as a disciplined, scalable growth platform heading into 2026. For the third quarter ended September 30, 2025, Marpai continued its turnaround trajectory, achieving meaningful advances in cost control,

    11/12/25 5:39:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI TO HOST WEBCAST ON NOVEMBER 13, 2025 TO DISCUSS THIRD QUARTER 2025 FINANCIAL RESULTS

    TAMPA, Fla., Nov. 6, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, November 13 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q3 2025. The Company will report its third quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q3 Financial Results Conference Call Date: November 13, 2025 Time: 8:30 a.m. Eastern Time Call: US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:  https://app.webinar.net/934VMynbB6a Follow us on X.com and LinkedIn You may str

    11/6/25 4:03:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    Marpai Slashes Losses by Two-Thirds in Q2 2025, Paving the Way to Profitability.Operating Expenses Cut 70% as Turnaround Gains Traction TAMPA, Fla., Aug. 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced second quarter 2025 results that mark a decisive step forward in its turnaround strategy. The Company delivered substantial quarterly year-over-year improvements across key financial metrics: Operating expenses down 70%, saving $9.9 millionOperating loss reduced by 71% to $3.6 million, an $8.7 million improvementNet loss reduced by 66% to $4.4 million, als

    8/13/25 4:07:00 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $MRAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    9/4/24 7:55:41 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    5/29/24 4:01:02 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care